GB2468424B - Methods and compositions for reduction of side effects of therapeutic treatments - Google Patents

Methods and compositions for reduction of side effects of therapeutic treatments

Info

Publication number
GB2468424B
GB2468424B GB1008749A GB201008749A GB2468424B GB 2468424 B GB2468424 B GB 2468424B GB 1008749 A GB1008749 A GB 1008749A GB 201008749 A GB201008749 A GB 201008749A GB 2468424 B GB2468424 B GB 2468424B
Authority
GB
United Kingdom
Prior art keywords
compositions
reduction
methods
side effects
therapeutic treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1008749A
Other versions
GB201008749D0 (en
GB2468424A (en
Inventor
Maryka Quik
Donato Di Monte
J William Langston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parkinsons Institute
Original Assignee
Parkinsons Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parkinsons Institute filed Critical Parkinsons Institute
Priority claimed from GB0805991A external-priority patent/GB2448224B/en
Publication of GB201008749D0 publication Critical patent/GB201008749D0/en
Publication of GB2468424A publication Critical patent/GB2468424A/en
Application granted granted Critical
Publication of GB2468424B publication Critical patent/GB2468424B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB1008749A 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments Expired - Fee Related GB2468424B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90963707P 2007-04-02 2007-04-02
US95629607P 2007-08-16 2007-08-16
US95665707P 2007-08-17 2007-08-17
GB0805991A GB2448224B (en) 2007-04-02 2008-04-02 Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent

Publications (3)

Publication Number Publication Date
GB201008749D0 GB201008749D0 (en) 2010-07-07
GB2468424A GB2468424A (en) 2010-09-08
GB2468424B true GB2468424B (en) 2011-11-09

Family

ID=42557247

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1008749A Expired - Fee Related GB2468424B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments

Country Status (1)

Country Link
GB (1) GB2468424B (en)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028801A1 (en) * 1996-02-09 1997-08-14 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US20040191322A1 (en) * 2002-12-20 2004-09-30 Henri Hansson Physically and chemically stable nicotine-containing particulate material
WO2005023226A1 (en) * 2003-09-05 2005-03-17 Arrow No. 7 Limited Buccal drug delivery
WO2005023227A2 (en) * 2003-09-08 2005-03-17 Pfizer Health Ab Nicotine formulations and use thereof
WO2007104574A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Chewing gum compositions providing rapid release of nicotine
WO2007133141A1 (en) * 2006-05-16 2007-11-22 Mcneil Ab Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
WO2008069921A2 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028801A1 (en) * 1996-02-09 1997-08-14 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US20040191322A1 (en) * 2002-12-20 2004-09-30 Henri Hansson Physically and chemically stable nicotine-containing particulate material
WO2005023226A1 (en) * 2003-09-05 2005-03-17 Arrow No. 7 Limited Buccal drug delivery
WO2005023227A2 (en) * 2003-09-08 2005-03-17 Pfizer Health Ab Nicotine formulations and use thereof
WO2007104574A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Chewing gum compositions providing rapid release of nicotine
WO2007133141A1 (en) * 2006-05-16 2007-11-22 Mcneil Ab Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
WO2008069921A2 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form

Also Published As

Publication number Publication date
GB201008749D0 (en) 2010-07-07
GB2468424A (en) 2010-09-08

Similar Documents

Publication Publication Date Title
GB2461412B (en) Methods and compositions for reduction of side effects of therapeutic treatments
ZA200908711B (en) Methods and compositions for treating allergic diseases
EP2211854A4 (en) Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
IL202015A0 (en) Methods and compositions for treating skin conditions
EP2293800A4 (en) Compositions and methods for treatment of ear disorders
EP2334315A4 (en) Agents and methods for treatment of pain
HK1159498A1 (en) Methods and compositions for the treatment of cancer
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2205236A4 (en) Novel agents for treatment of ailments and dysfunctions
HK1245679A1 (en) Methods and compositions for treating dermatological diseases and conditions
ZA201006988B (en) Method and compositions for treatment of cancer
EP2340027A4 (en) Methods and compositions for the treatment of cancer
EP2271352A4 (en) Compositions and methods for treatment of neoplastic disease
HK1160598A1 (en) Compositions and methods for treatment of kidney disorders
EP2217238A4 (en) Methods and compositions for the treatment of proteinuric diseases
EP2176406A4 (en) Compositions and methods of treating cancer
EP2150270A4 (en) Methods and compositions for the treatment of cancer
EP2096927A4 (en) Therapeutic compositions and methods of treatment with capsianoside-type compounds
PL2331092T3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
GB2468424B (en) Methods and compositions for reduction of side effects of therapeutic treatments
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
AU2007900995A0 (en) Therapeutic Compositions and Methods of Treatment
EP2276502A4 (en) Compositions for the prevention and treatment of neuroinjury and methods of use thereof
IL209658A0 (en) Compositions and methods for treatment of ear disorders

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147951

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1147951

Country of ref document: HK

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20160402